Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

2023741 citationsJournal Articlegreen Open Access

Authors

Mansoor Raza Mirza · Nordic Society of Gynecologic Oncology

Dana M. Chase · Nordic Society of Gynecologic Oncology

Brian M. Slomovitz · Florida International University

René dePont Christensen · Nordic Society of Gynecologic Oncology

Zoltán Novàk · Copenhagen University Hospital

Destin Black · Nordic Society of Gynecologic Oncology

Lucy Gilbert

Abstract

Dostarlimab plus carboplatin-paclitaxel significantly increased progression-free survival among patients with primary advanced or recurrent endometrial cancer, with a substantial benefit in the dMMR-MSI-H population. (Funded by GSK; RUBY ClinicalTrials.gov number, NCT03981796.).

Topics & Keywords

Endometrial and Cervical Cancer Treatments Ovarian cancer diagnosis and treatment Sarcoma Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 388, Issue 23, pp. 2145-2158

DOI: 10.1056/nejmoa2216334

Field-Weighted Citation Impact: 218.88